Wooridul Pharmaceutical announced on Feb. 25 that it has signed an agreement on new bio drug development with Seoul National University Bio-MAX/N-Bio. The agreement was based on an MOU the two organizations signed in December 2020.
Wooridul Pharmaceutical and the SNU research institute have launched two tasks — the development of disease treatments through big data analysis and the development of a disease treatment target prediction system using big data and deep learning.
Wooridul Pharmaceutical plans to use AI technology and big data analysis techniques possessed by the SNU research institute to develop treatments for incurable diseases such as diabetes and dementia. The company looks to drastically cut the cost and period of new drug development and research through this partnership.